Abbott Receives FDA Approval for Tendyne™

Abbott Gains FDA Approval for Tendyne™, the First Device to Replace the Mitral Valve Without Open-Heart Surgery

Abbott has announced that its Tendyne™ transcatheter mitral valve replacement (TMVR) system just received FDA approval, marking a significant milestone in the treatment of mitral valve disease. This new option targets patients suffering from severe mitral annular calcification (MAC)—a condition where calcium builds up in the mitral valve’s supporting ring, leading to serious valve dysfunction.

Treating mitral valve disease is notoriously complex, especially in patients with severe MAC. Many of these individuals are considered too high-risk for traditional open-heart-surgery and some are not candidates for repair with Abbott’s MitraClip™ device. Tendyne™ now provides a minimally invasive alternative for these high-risk patients, offering a new solution for those experiencing severe mitral regurgitation or stenosis.

Dr. Paul Sorajja, a leading expert from the Minneapolis Heart Institute, emphasized that MAC can make the mitral valve stiff and lead to symptoms like chest pain, shortness of breath, and dizziness, all of which significantly impact quality of life. He noted that Tendyne addresses a critical gap in care, enabling physicians to treat patients who previously had very limited options. This approval positions Tendyne as an important advancement for both physicians and patients confronting the challenges of severe mitral valve disease.

Abbott’s Tendyne system stands out for its flexible, innovative design, offering a range of valve sizes to accommodate diverse patient anatomies. The self-expanding valve is delivered through a minimally invasive incision, then positioned precisely in the heart to replace the mitral valve. The best part - Physicians can reposition or even retrieve the valve during the procedure, which really raises the bar for patient outcomes.

Sandra Lesenfants, who heads up Abbott’s structural heart division, summed it up well: “Tendyne is a significant addition to our U.S. structural heart portfolio, expanding minimally invasive options for patients with complex heart conditions.” She emphasized that this latest approval builds on Abbott’s more than twenty years of leadership and innovation in mitral valve therapy—underscoring the company’s commitment to advancing cardiac care and improving patient lives.

We’d love to hear your perspective—drop a comment!